Neurimmune has sold part of its royalty interest in cliramitug, an investigational antibody for transthyretin amyloid cardiomyopathy, to Royalty Pharma plc for payments of up to $425 million. Royalty Pharma will receive a 3% to 4% royalty on worldwide net sales if the Phase 3 candidate reaches the market, while Alexion, AstraZeneca Rare Disease continues to control its development, manufacturing and commercialisation.
The transaction gives privately held Neurimmune substantial non-dilutive capital without requiring it to surrender its entire economic interest in cliramitug. It also gives Royalty Pharma exposure to a late-stage programme that could introduce a different therapeutic approach to the rapidly expanding transthyretin amyloid cardiomyopathy, or ATTR-CM, market.
That distinction matters. Cliramitug is not approved, and the transaction does not reduce the clinical or regulatory uncertainty surrounding it. Royalty Pharma is effectively exchanging near-term capital for a share of possible future sales, with part of its financial commitment tied to clinical and regulatory progress.
How does the $425 million cliramitug royalty transaction divide payment and development risk?
Royalty Pharma will pay Neurimmune $125 million upfront and is scheduled to provide another $125 million during the first quarter of 2027. The remaining $175 million is contingent upon undisclosed clinical and regulatory milestones.
The structure therefore separates the headline value from the amount Neurimmune is assured of receiving in the nearer term. The first two payments would provide $250 million in cash through early 2027, while the final portion depends on cliramitug progressing successfully through specified development events.
In return, Royalty Pharma will receive a 3% to 4% royalty on worldwide net sales. The precise mechanics of the range, including any sales thresholds that determine the applicable percentage, were not disclosed.
Royalty Pharma is not purchasing cliramitug itself, taking control of the programme or assuming responsibility for the Phase 3 trial. Alexion remains responsible for development, manufacturing and commercialisation under the global collaboration and licence agreement signed with Neurimmune in 2022.
This creates a clear allocation of responsibilities. AstraZeneca carries the operational burden of turning the investigational antibody into a potential commercial medicine, Royalty Pharma provides capital in exchange for future sales participation, and Neurimmune converts part of a long-dated royalty into funding while retaining the majority of its royalty and milestone interests.
Why is cliramitug’s amyloid-depletion mechanism different from existing ATTR-CM therapies?
ATTR-CM is caused by the accumulation of misfolded transthyretin protein as amyloid deposits in the heart. Those deposits can make the heart muscle thicker and less flexible, progressively impairing its ability to fill and pump effectively.
Existing approved disease-modifying treatments include transthyretin stabilisers and gene-silencing therapies. These approaches are intended to reduce the formation of additional amyloid by stabilising the transthyretin protein or lowering its production.
Cliramitug, formerly known as NI006 and ALXN2220, is designed to address another part of the disease process. The recombinant human monoclonal antibody selectively recognises disease-associated transthyretin amyloid and is intended to promote immune-mediated clearance of deposits already present in the heart while sparing normal transthyretin.
If that mechanism translates into better clinical outcomes, cliramitug could potentially be used alongside therapies that reduce continued amyloid formation. The commercial opportunity may therefore depend less on replacing every established treatment and more on demonstrating meaningful additional benefit when administered against a background of contemporary care.
That possibility remains unconfirmed. Removing or reducing amyloid on imaging does not automatically establish that patients will live longer, avoid cardiovascular events or experience sustained functional improvement. The Phase 3 programme must connect the biological effect to outcomes that matter clinically.
How persuasive is the early cliramitug evidence before the Phase 3 readout?
The original NI006-101 first-in-human study used a randomised, double-blind, placebo-controlled dose-escalation design. Forty adults with wild-type or hereditary ATTR-CM and chronic heart failure were assigned in a two-to-one ratio to intravenous cliramitug or placebo during the initial treatment period.
The published results indicated dose-dependent and time-dependent reductions in surrogate measures of cardiac amyloid burden at higher doses. Changes were observed using cardiac magnetic resonance imaging and scintigraphy, alongside reductions in biomarkers associated with cardiac stress and injury.
Longer-term findings published in 2026 added data from 23 participants who entered a second open-label extension. These participants received a median of 10 additional infusions, extending median follow-up to 29.3 months. Twenty of the 23 were receiving tafamidis, and every participant in the extension was male.
The investigators reported no treatment-related serious adverse events or discontinuations in that extension cohort. They also observed further changes in imaging markers, cardiac biomarkers and selected measures of cardiac structure and function.
These findings strengthen the rationale for continued development, but they are not equivalent to confirmatory efficacy evidence. The extension involved a small, selected group of patients, lacked a concurrent placebo comparison and included variable cumulative doses. Its all-male population also limits conclusions about whether the findings will apply consistently across the broader ATTR-CM population.
The heavy use of tafamidis is commercially interesting because it offers an early view of cliramitug on top of a stabiliser. However, it also makes it difficult to isolate the antibody’s contribution to longer-term clinical changes without a sufficiently powered controlled study.
What must the DepleTTR-CM trial prove beyond reductions in cardiac amyloid markers?
Cliramitug is being evaluated in the Phase 3 DepleTTR-CM trial, a randomised, double-blind, placebo-controlled international study involving more than 1,100 adults with ATTR-CM. Participants receive cliramitug or placebo through an intravenous infusion every four weeks, and background standard-of-care treatment is permitted.
The primary endpoint is designed to assess all-cause mortality and clinically important cardiovascular events. This is a much more demanding test than measuring changes in imaging or laboratory biomarkers, but it is also the evidence needed to determine whether amyloid depletion produces a meaningful improvement in the disease course.
Royalty Pharma said Phase 3 results are expected in 2028, based on AstraZeneca’s guidance. Until those data emerge, the central question is whether removing existing cardiac amyloid can produce incremental benefits beyond therapies that suppress new accumulation.
Safety will also require close scrutiny. Activating immune-mediated clearance inside a heart already affected by progressive amyloid disease introduces considerations that cannot be settled by a small early-stage dataset. The Phase 3 trial should offer a substantially stronger assessment of serious adverse events, infusion reactions, treatment discontinuations and any consequences associated with prolonged amyloid clearance.
Cliramitug has received Fast Track designation from the United States Food and Drug Administration for development in ATTR-CM. That designation can facilitate interaction with the regulator, but it is not an approval and does not establish efficacy, safety or the eventual timing of a marketing decision.
Why does the partial royalty sale strengthen Neurimmune without ending its cliramitug exposure?
Neurimmune said the proceeds would fund its internal research and development programmes. Its pipeline includes AP-101 for amyotrophic lateral sclerosis, NG004 for spinal cord injury and additional antibody programmes targeting protein aggregation diseases.
For a privately held biotechnology company, obtaining $250 million in scheduled cash without issuing equity can materially improve strategic flexibility. It can fund clinical work, expand internal programmes and reduce the need to raise capital under less favourable conditions.
The trade-off is that Neurimmune has surrendered part of the future cash flow it could receive if cliramitug becomes a major commercial product. Nevertheless, retaining the majority of its royalty and milestone interests means the company remains economically aligned with the programme’s success.
The approach resembles portfolio financing more than a conventional asset divestment. Neurimmune is using one comparatively mature partnered programme to finance earlier and riskier assets while preserving meaningful participation in cliramitug’s upside.
This strategy is attractive when capital is scarce and future royalty payments remain several years away. Its ultimate quality, however, will depend on how efficiently Neurimmune deploys the proceeds and whether the programmes being financed create value beyond the economic interest sold.
What does the cliramitug acquisition add to Royalty Pharma’s development-stage portfolio?
Royalty Pharma’s investment rests on both cliramitug’s differentiated mechanism and the commercial expansion of ATTR-CM treatment. The company estimated that the ATTR-CM market exceeded $7 billion in 2025 after growing more than 40%, supported by improving diagnosis and the arrival of additional treatment options.
AstraZeneca has previously outlined a non-risk-adjusted peak-year revenue target of $3 billion to $5 billion for cliramitug. Applying the disclosed 3% to 4% royalty range to those sales assumptions would imply an illustrative annual royalty of approximately $90 million to $200 million at peak.
That calculation is not a revenue forecast. It does not account for development failure, regulatory decisions, the timing of launch, the shape of the commercial ramp, the exact royalty tiers, treatment duration, competitive changes or the remaining life of the applicable royalty rights.
Royalty Pharma has the financial capacity to absorb this type of long-duration risk. The company generated $925 million in portfolio receipts and $718 million in operating cash flow during the first quarter of 2026. It also raised its full-year portfolio receipts guidance to between $3.325 billion and $3.45 billion.
The cliramitug transaction adds another development-stage asset rather than an immediate revenue stream. Its contribution will remain speculative until Phase 3 results clarify the clinical value of amyloid depletion and regulators determine whether the evidence supports approval.
How should investors read Royalty Pharma’s share-price strength after the transaction?
Royalty Pharma shares traded near $58.42 on July 22, approximately 2% above the previous close and close to the upper end of their 52-week range of $34.08 to $59.44. The stock had gained roughly 4.9% over five trading days and about 10.3% over one month at the latest check.
The positive market backdrop should not be attributed solely to the cliramitug transaction. Royalty Pharma entered the announcement with improving portfolio receipts, raised annual guidance and broader investor interest in its capital-deployment strategy.
For shareholders, cliramitug is better viewed as a long-term portfolio option than a near-term earnings catalyst. The initial $125 million payment is manageable relative to Royalty Pharma’s cash generation, but the asset will not produce royalties unless it receives regulatory approval and generates commercial sales.
The next value-defining event is therefore not the closing of the royalty transaction. It is the DepleTTR-CM readout expected in 2028. That study must show whether the encouraging amyloid, biomarker and cardiac-function signals observed in early development translate into fewer deaths or serious cardiovascular events.
If it succeeds, Royalty Pharma will have secured participation in a potentially large new ATTR-CM revenue stream, while Neurimmune will retain meaningful economics after financing its broader pipeline. If it fails, the milestone-based structure will limit part of Royalty Pharma’s commitment, but the upfront and scheduled payments will still represent capital placed at clinical risk.
